Rep. Sharice Davids

Maddy summaryThe Born to Invest Act of 2026 directs the Treasury Secretary, working with the Health and Human Services Secretary, to create model guidance for state officials. This guidance is intended to help state treasurers inform parents and legal guardians about opening specific tax-advantaged accounts for children, including Trump accounts, ABLE programs, and tuition programs. Additionally, the bill outlines procedures for state health departments to coordinate with treasurers by sharing live birth data to facilitate these account notifications.

Maddy summaryThe Reverse Big Ugly Tax Breaks for Data Centers Act removes specific tax incentives for large-scale data centers and artificial intelligence facilities. It excludes these facilities from bonus depreciation, a provision that currently allows businesses to deduct the full cost of certain equipment in the year it is purchased. Additionally, the bill prevents these properties from qualifying as opportunity zone business property, which would otherwise offer significant tax benefits for investments in designated areas. The legislation targets structures with a power capacity exceeding 50 megawatts that are dedicated to data storage, processing, or AI operations.

Maddy summaryThe Survivor Benefits Application Modernization Act requires the Commissioner of Social Security to create an online portal for individuals applying for survivor insurance benefits. This portal must first allow users to schedule appointments within 180 days of enactment and later enable them to file their applications entirely online within one year. The bill directly affects people seeking these specific benefits by providing a digital alternative to traditional in-person or paper-based processes. Additionally, the law mandates that the Commissioner submit a report to Congress three years after enactment detailing changes in application volume, costs, and fraud rates resulting from the new system.

Maddy summaryThis bill would require Medicare to cover early detection screening tests for Alzheimer's disease and related dementias starting January 1, 2028. It defines eligible tests as FDA-cleared genomic blood tests, blood product analyses, or equivalent medical imaging methods (like protein expression or whole genome sequencing) that detect pre-symptomatic or early-stage conditions. Medicare beneficiaries would receive this coverage without cost-sharing for these specific screenings. The bill amends Medicare coverage rules to explicitly include these tests under Section 1861(nnn) of the Social Security Act.

Maddy summaryThis bill creates a 6-year Medicare pilot program providing medically tailored home-delivered meals and nutrition counseling to specific high-risk Medicare patients after hospital discharge. It targets individuals with diet-impacted conditions (like diabetes or heart failure) who live at home, have limited mobility, and are at high risk of hospital readmission. Selected hospitals must meet quality standards, screen patients using approved tools, and deliver at least two meals daily meeting nutritional needs while respecting cultural/religious dietary requirements, all without patient cost-sharing. The program requires hospitals to submit data for the Secretary to evaluate health outcomes, readmission rates, and cost savings compared to non-participants. Funding comes from the Medicare Hospital Insurance Trust Fund, offset by reductions to other hospital payments to maintain budget neutrality.

Maddy summaryThe TRAPS Act establishes a federal Task Force on Payment Scams, chaired by the Treasury Secretary, to coordinate efforts across agencies like the FTC, Federal Reserve, and consumer groups. The Task Force will study current scam tactics (such as fake text messages or fraudulent payment platforms), evaluate prevention strategies, and develop recommendations to help consumers avoid and report scams. It must submit an initial report within one year and annual updates, focusing on improving federal-state coordination and education programs. This bill directly affects government agencies and stakeholders participating in the Task Force, with the goal of protecting consumers from evolving payment scams.

Maddy summaryThis bill requires federal agencies to provide small business contractors with interim partial payments of at least 50% of estimated costs when contract terms change without the business's agreement. It directly affects small businesses awarded federal construction contracts and their subcontractors, ensuring they receive upfront funds to cover increased costs from mandated changes. The key mechanism mandates that agencies issue these payments promptly upon valid requests, with small businesses required to pass the funds to relevant subcontractors. The law also specifies that these interim payments do not finalize the adjustment request, preserving the agency's right to review the full claim later.

Maddy summaryHR 2004, titled "Tyler’s Law," requires the Secretary of Health and Human Services to study how often hospital emergency departments test for fentanyl during overdose cases (beyond standard drug tests), including associated costs, patient benefits/risks, and impacts on privacy and patient-physician relationships. The study must be completed within one year of the bill's enactment. Based on the study results, the Secretary must issue guidance within six months on whether emergency departments should routinely test for fentanyl, how to inform clinicians about test contents, and how such testing may affect future overdose risks and health outcomes. This bill directly affects hospital emergency departments and patients experiencing overdoses by shaping future testing protocols.

Maddy summaryHR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.